Eur Rev Med Pharmacol Sci 2022; 26 (2): 653-663

DOI: 10.26355/eurrev_202201_27892

Association among CO-RADS score, co-morbid diseases, and short-term prognosis in COVID-19 infection

I.H. Inanc, N. Bursa, A. Gultepe, M. Bayramoğlu, C. Sabanoglu, F.A. Inanc

Department of Cardiology, Besni State Hospital, Adıyaman, Turkey. dr.ibrahimhalilinanc@outlook.com


OBJECTIVE: CO-RADS scoring system is used as a diagnostic tool. However, the data about its association with co-morbid diseases and effectiveness in predicting intensive care need and short-term mortality are lacking. In our study, we aimed to investigate the association among CO-RADS score, co-morbid diseases, intensive care need, and 28-day-mortality.

PATIENTS AND METHODS: The study included 665 patients with COVID-19 infection suspicion between 30 May 2020 and 30 October 2020.

RESULTS: The sensitivity of CT was 77%, and specificity was 52%. A higher CT score was associated with the rate of positive PCR test results (p<0.001), and older patients had higher CO-RADS scores than younger patients (p<0.001). Hypertension (OR: 7.956; p=0.005) and diabetes mellitus (OR: 5.902; p=0.015) were associated with significantly higher CO-RADS scores. Most patients treated in the intensive care unit (ICU) had a CO-RADS score of 5. The CO-RADS score was 4 and above in 115 (89.2%) patients who were transferred to the intensive care unit due to worsening of clinical condition (p<0.001). The 28-day mortality was significantly higher in patients with a CO-RADS score of 4 and above than in patients with a score of 3 and below (97.3% vs. 2.7%) (p<0.001).

CONCLUSIONS: Irrespective of PCR results, a higher CO-RADS score gives us useful information about ICU need or mortality risk and alerts us for early treatment to reduce the risk of further transmission, intensive care need, and mortality particularly in patients with co-morbid diseases.

Free PDF Download

To cite this article

I.H. Inanc, N. Bursa, A. Gultepe, M. Bayramoğlu, C. Sabanoglu, F.A. Inanc
Association among CO-RADS score, co-morbid diseases, and short-term prognosis in COVID-19 infection

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 2
Pages: 653-663
DOI: 10.26355/eurrev_202201_27892